|
|
 Previous Article | Table of Contents | Next Article 
Pgp and MRP Activities Using Calcein-AM Are Prognostic Factors in
Adult Acute Myeloid Leukemia Patients
Ollivier Legrand,
Ghislaine Simonin,
Jean-Yves Perrot,
Robert Zittoun, and
Jean-Pierre Marie
From the Service d'Hématologie Clinique, the Service
d'Hématologie Biologique, and the Formation de Recherche
Associée Claude Bernard sur le Traitement des Hémopathies
Malignes, Laboratoire Universitaire Paris VI, Paris,
France.
Thirteen cell lines with different levels of Pgp and MRP expression
were used to assess the ability of calcein acetoxymethyl ester
(calcein-AM) uptake and calcein efflux to measure Pgp and MRP
functions, respectively. There was a good correlation between MRP
expression and the modulatory effect of probenecid (a specific modulator of MRP) on the calcein efflux (r = .91, P
= .0003) and between Pgp expression and the modulatory effect of CsA
on calcein-AM uptake (r = .96, P < .0001). In light
of the high correlations for both proteins, we tested calcein-AM uptake
and efflux in fresh myeloid leukemic cells. In 53 acute myeloid
leukemia (AML) patients, there was also a good correlation between MRP
expression (measured by reverse transcription-polymerase chain
reaction and by MRPm6 expression by flow cytometry) and
the modulatory effect of probenecid on the calcein fluorescence
(r = .92, P < .0001) and between Pgp expression as
measured by UIC2 antibody binding on flow cytometry and the modulatory
effect of cyclosporin A on calcein-AM uptake (r = .83, P < .0001). Pgp activity was higher in CD34+
leukemia than in CD34 leukemia (2.26 ± 1.50 v
1.46 ± 1.21, respectively; P = .003), and MRP activity was
higher in CD34 leukemia than in CD34+
leukemia (1.77 ± 0.40 v 1.4 ± 0.29, respectively; P
= .004). Pgp expression and activity (P = .004 and
P = .01, respectively) and MRP activity (P = .03)
but not MRP expression were prognostic factors for achievement of
complete remission. These results suggest that functional
testing (with calcein-AM ± modulators) for the presence of both MRP
and Pgp activities is of prognostic value and that MRP contributes to
drug resistance in AML.
Blood, Vol. 91 No. 12 (June 15), 1998:
pp. 4480-4488
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Bousquet, A. Pruvost, A.-C. Guyot, R. Farinotti, and A. Mabondzo
Combination of Tenofovir and Emtricitabine plus Efavirenz: In Vitro Modulation of ABC Transporter and Intracellular Drug Accumulation
Antimicrob. Agents Chemother.,
March 1, 2009;
53(3):
896 - 902.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Weisburg
Multidrug Resistance in Acute Myeloid Leukemia: Potential New Therapeutics
J. Nucl. Med.,
September 1, 2008;
49(9):
1405 - 1407.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Lai, L. Xing, G. I. Poda, and Y. Hu
Structure-Activity Relationships for Interaction with Multidrug Resistance Protein 2 (ABCC2/MRP2): The Role of Torsion Angle for a Series of Biphenyl-Substituted Heterocycles
Drug Metab. Dispos.,
June 1, 2007;
35(6):
937 - 945.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Benderra, A. M. Faussat, L. Sayada, J.-Y. Perrot, R. Tang, D. Chaoui, H. Morjani, C. Marzac, J.-P. Marie, and O. Legrand
MRP3, BCRP, and P-Glycoprotein Activities are Prognostic Factors in Adult Acute Myeloid Leukemia
Clin. Cancer Res.,
November 1, 2005;
11(21):
7764 - 7772.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Qadir, K. L. O'Loughlin, S. M. Fricke, N. A. Williamson, W. R. Greco, H. Minderman, and M. R. Baer
Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator
Clin. Cancer Res.,
March 15, 2005;
11(6):
2320 - 2326.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Benderra, A.-M. Faussat, L. Sayada, J.-Y. Perrot, D. Chaoui, J.-P. Marie, and O. Legrand
Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias
Clin. Cancer Res.,
December 1, 2004;
10(23):
7896 - 7902.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Walter, B. W. Raden, M. R. Cronk, I. D. Bernstein, F. R. Appelbaum, and D. E. Banker
The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin
Blood,
June 1, 2004;
103(11):
4276 - 4284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Geromin, J.-F. Bourge, A. Soulie, R. Pawliuk, C. Fleet, E. Michel, Y. Denizot, C. Berthou, P. Leboulch, F. Sigaux, et al.
Glycoprotein 170 Induces Platelet-Activating Factor Receptor Membrane Expression and Confers Tumor Cell Hypersensitivity to NK-Dependent Cell Lysis
J. Immunol.,
March 15, 2004;
172(6):
3604 - 3611.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hamada, H. Miyano, H. Watanabe, and H. Saito
Interaction of Imatinib Mesilate with Human P-Glycoprotein
J. Pharmacol. Exp. Ther.,
November 1, 2003;
307(2):
824 - 828.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. A. Plasschaert, D. M. van der Kolk, E. S. J. M. de Bont, W. A. Kamps, K. Morisaki, S. E. Bates, G. L. Scheffer, R. J. Scheper, E. Vellenga, and E. G. E. de Vries
The Role of Breast Cancer Resistance Protein in Acute Lymphoblastic Leukemia
Clin. Cancer Res.,
November 1, 2003;
9(14):
5171 - 5177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Brooks, H. Minderman, K. L. O'Loughlin, P. Pera, I. Ojima, M. R. Baer, and R. J. Bernacki
Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein
Mol. Cancer Ther.,
November 1, 2003;
2(11):
1195 - 1205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Solary, B. Drenou, L. Campos, P. de Cremoux, F. Mugneret, P. Moreau, B. Lioure, A. Falkenrodt, B. Witz, M. Bernard, et al.
Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia
Blood,
August 15, 2003;
102(4):
1202 - 1210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Walter, B. W. Raden, T. C. Hong, D. A. Flowers, I. D. Bernstein, and M. L. Linenberger
Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells
Blood,
August 15, 2003;
102(4):
1466 - 1473.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Steinbach, J. Lengemann, A. Voigt, J. Hermann, F. Zintl, and A. Sauerbrey
Response to Chemotherapy and Expression of the Genes Encoding the Multidrug Resistance-associated Proteins MRP2, MRP3, MRP4, MRP5, and SMRP in Childhood Acute Myeloid Leukemia
Clin. Cancer Res.,
March 1, 2003;
9(3):
1083 - 1086.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Ohno, A. Tani, Z.-S. Chen, K. Uozumi, S. Hanada, S. Akiba, X.-Q. Ren, T. Furukawa, T. Sumizawa, T. Arima, et al.
Prognostic Significance of Multidrug Resistance Protein in Adult T-cell Leukemia
Clin. Cancer Res.,
October 1, 2001;
7(10):
3120 - 3126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Linenberger, T. Hong, D. Flowers, E. L. Sievers, T. A. Gooley, J. M. Bennett, M. S. Berger, L. H. Leopold, F. R. Appelbaum, and I. D. Bernstein
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin
Blood,
August 15, 2001;
98(4):
988 - 994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Witt, J. D. Huber, R. D. Egleton, M. J. Roberts, M. D. Bentley, L. Guo, H. Wei, H. I. Yamamura, and T. P. Davis
Pharmacodynamic and Pharmacokinetic Characterization of Poly(Ethylene glycol) Conjugation to Met-Enkephalin Analog [D-Pen2,D-Pen5]-enkephalin (DPDPE)
J. Pharmacol. Exp. Ther.,
August 1, 2001;
298(2):
848 - 856.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. van den Heuvel-Eibrink, E. A. C. Wiemer, M. J. de Boevere, B. van der Holt, P. J. M. Vossebeld, R. Pieters, and P. Sonneveld
MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia
Blood,
June 1, 2001;
97(11):
3605 - 3611.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Legrand, J.-Y. Perrot, G. Simonin, M. Baudard, and J.-P. Marie
JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia
Blood,
January 15, 2001;
97(2):
502 - 508.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Takemura, Y. Urasaki, A. Yoshida, T. Fukushima, and T. Ueda
Simultaneous Treatment with 1-{beta}-D-Arabinofuranosylcytosine and Daunorubicin Induces Cross-Resistance to Both Drugs due to a Combination-specific Mechanism in HL60 Cells
Cancer Res.,
January 1, 2001;
61(1):
172 - 177.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. M. van der Kolk, E. G. E. de Vries, W. L. J. van Putten, L. F. Verdonck, G. J. Ossenkoppele, G. E. G. Verhoef, and E. Vellenga
P-glycoprotein and Multidrug Resistance Protein Activities in Relation to Treatment Outcome in Acute Myeloid Leukemia
Clin. Cancer Res.,
August 1, 2000;
6(8):
3205 - 3214.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
O. Legrand, J.-Y. Perrot, M. Baudard, A. Cordier, R. Lautier, G. Simonin, R. Zittoun, N. Casadevall, and J.-P. Marie
The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score
Blood,
August 1, 2000;
96(3):
870 - 877.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. van der Kolk, E. Vellenga, A. Y. van der Veen, L. Noordhoek, H. Timmer-Bosscha, G. J. Ossenkoppele, R. A. Raymakers, M. Muller, E. van den Berg, and E. G. E. de Vries
Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity
Blood,
June 1, 2000;
95(11):
3514 - 3519.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Epsztejn, H. Glickstein, V. Picard, I. N. Slotki, W. Breuer, C. Beaumont, and Z. I. Cabantchik
H-Ferritin Subunit Overexpression in Erythroid Cells Reduces the Oxidative Stress Response and Induces Multidrug Resistance Properties
Blood,
November 15, 1999;
94(10):
3593 - 3603.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Legrand, G. Simonin, A. Beauchamp-Nicoud, R. Zittoun, and J.-P. Marie
Simultaneous Activity of MRP1 and Pgp Is Correlated With In Vitro Resistance to Daunorubicin and With In Vivo Resistance in Adult Acute Myeloid Leukemia
Blood,
August 1, 1999;
94(3):
1046 - 1056.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Leith, K. J. Kopecky, I-M. Chen, L. Eijdems, M. L. Slovak, T. S. McConnell, D. R. Head, J. Weick, M. R. Grever, F. R. Appelbaum, et al.
Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study
Blood,
August 1, 1999;
94(3):
1086 - 1099.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. F. Hu, A. Slater, P. Kantharidis, D. Rischin, S. Juneja, R. Rossi, G. Lee, J. D. Parkin, and J. R. Zalcberg
Altered Multidrug Resistance Phenotype Caused by Anthracycline Analogues and Cytosine Arabinoside in Myeloid Leukemia
Blood,
June 15, 1999;
93(12):
4086 - 4095.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
